41 results
S-1
VERV
Verve Therapeutics Inc
28 May 21
IPO registration
4:04pm
, extensive healthcare infrastructure and regular healthcare access – and leaves many patients without adequate care. Our goal is to disrupt the chronic care … the chronic care model for treating patients with or at risk for ASCVD and relieve the significant burden placed on patients, providers and the healthcare
S-1/A
VERV
Verve Therapeutics Inc
14 Jun 21
IPO registration (amended)
6:15am
rigorous patient adherence, extensive healthcare infrastructure and regular healthcare access – and leaves many patients without adequate care. Our … on patients, providers and the healthcare system.
Our approach leverages multiple breakthroughs in 21st century biomedicine—human genetic analysis, gene
DRS
VERV
Verve Therapeutics Inc
16 Apr 21
Draft registration statement
12:00am
adherence, extensive healthcare infrastructure and regular healthcare access – and leaves many patients without adequate care. Our goal is to disrupt … and the healthcare system.
Our approach leverages multiple breakthroughs in 21st century biomedicine—human genetic analysis, gene editing, messenger RNA
424B4
VERV
Verve Therapeutics Inc
17 Jun 21
Prospectus supplement with pricing info
4:50pm
adherence, extensive healthcare infrastructure and regular healthcare access – and leaves many patients without adequate care. Our goal is to disrupt … and the healthcare system.
Our approach leverages multiple breakthroughs in 21st century biomedicine—human genetic analysis, gene editing, messenger
10-Q
2021 Q2
VERV
Verve Therapeutics Inc
12 Aug 21
Quarterly report
8:53am
remains the leading cause of death worldwide. The current paradigm of chronic care is fragile—requiring rigorous patient adherence, extensive healthcare … infrastructure and regular healthcare access—and leaves many patients without adequate care. Our goal is to disrupt the chronic care model for CVD
8-K
EX-99.1
4fqn92
15 May 23
Verve Therapeutics Announces Pipeline Progress and Expansion and Reports First Quarter 2023 Financial Results
7:00am
10-K
753hqpsnj
14 Mar 22
Annual report
7:04am
8-K
EX-99.1
c17sl5qp4yfwv
10 Nov 21
Verve Therapeutics Announces Pipeline Progress and Reports Third Quarter 2021 Financial Results
6:56am
8-K
EX-99.1
dkuujdoobrv7
7 Nov 23
Verve Therapeutics Highlights Recent Company Progress and Reports Third Quarter 2023 Financial Results
7:00am
S-1
EX-10.1
85jc217 lun
28 May 21
IPO registration
4:04pm